MedTech-related technology assessments and clinical guidelines from NICE in August 2022

13

Sep 2022

Interventional Procedures Guidance (IPG) is developed for most of the novel interventional procedures entering the English market. The program focuses solely on clinical evidence. Recommendations may vary from "for research only" to "for use with standard arrangements for clinical governance, consent, and audit." Recommendations are not binding, although they are followed by providers and commissioners.

In August 2022, NICE published five new IPGs and made the following conclusions:

The MedTech Innovation Briefings (MIBs) is the advice program of NICE for innovative technologies. It provides an overview of clinical effectiveness, safety, and cost. It does not offer formal guidance, and it, therefore, does not provide any recommendations. Three new MIBs published in August 2022 are:

Medical Technologies Guidance (MTG) evaluates new, innovative medical devices and diagnostics. It looks at medical technologies that deliver treatment, like those implanted during surgical procedures, give greater independence to patients, or detect or monitor medical conditions.

In August 2022, NICE updated two MTGs:

Two clinical guidelines were updated in August 2022:

See the full details for guidance here and for MIBs here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

23

Sep 2022

On September 5, 2022, it was announced that the Interterritorial Council for the Spanish National Health System (CISNS) approved the distribution of funds to the Autonomous Communities for the fight against cancer. The aim is to boost the screening programs for colorectal and cervical cancer.

Read more

22

Sep 2022

On September 01, 2022, NHS England published an update of the Specialized Services Policy Pipeline (as of August 24, 2022). Two new MedTech-related Clinical Commissioning Policies were added to the work program (transcatheter edge-to-edge repair of the mitral valve, pectus surgery for really severe pectus), and no new policies were published. The status of ongoing policies was updated as well.

Read more

21

Sep 2022

In September 2022, Ordering Forum for New Methods has invited interested parties regarding electric field therapy (Optune, Tumor Treating Fields) alone or in combination with drugs for certain groups of glioblastoma patients, based on genome sequencing and biomarkers (indication II). Information should be submitted before November 8, 2022. Ordering Forum will be held on November 21, 2022, to decide whether the method will undergo evaluation at the national level.

Read more

16

Sep 2022

In August 2022, the National Institute for Health and Care Research (NIHR) in England released two MedTech-related reports in its Health Technology Assessment (HTA) Journal, which concerned the treatment of urodynamic stress incontinence after prostate surgery and closure techniques after surgery for colorectal cancer. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.

Read more

15

Sep 2022

On August 25, 2022, the Norwegian Directorate of Health announced the launch of the National screening program for colorectal cancer (Bowel screening program - Tarmscreeningprogrammet). All 55-year-old men and women will be included in the program and offered a test to identify invisible blood in the stool (fecal immunochemical test, FIT) every two years until the age of 65. Colonoscopy will be offered in case of positive FIT.

Read more